SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Clinical trial NCT05480865 · TERMINATED

Trial details

NCT number: NCT05480865
Sponsor: Navire Pharma Inc., a BridgeBio company
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor, Adult Metastatic Solid Tumor Metastatic NSCLC Non Small Cell Lung Cancer

Start date: 2022-07-06
Primary completion: 2024-08-22
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.